Modular Medical, Inc.

Initial patients expected in June 2026

• Meet with Modular Medical CEO Jeb Besser

• Discover Modular Medical's Pivot, the first FDA-cleared, two-part tubeless patch pump featuring a removable 3 mL reservoir, disposable battery, smartphone connectivity for bolus and monitoring, and true electronic accuracy without tubes or constant wear and its associated commercial & manufacturing timeline.

First Removable 2-Part Design Targets $3 Billion "Almost-Pumper" Market with Expected Q2 2026 initial deployment.

Key Milestones & Investment Highlights:

• FDA 510(k) Clearance Achieved: Pivot^™ pump now cleared for commercial sale in the U.S. - major de-risking event unlocking revenue path.

• First-in-Class Removable Tubeless Patch Pump: 3 mL detachable reservoir; no battery recharging required; removable for showering, sports or discretion; quick bolus button without a separate controller.

• Targets Massive Underserved Market: ~70% of insulin-dependent adults remain on multiple daily injections (MDI) due to complexity, cumbersomeness and cost - Pivot addresses the "3 Cs" for "almost-pumpers" with its 2-part reusable pump.

• Manufacturing Readiness: Production validation lots well underway; initial capacity supports ~6,000 users with scalable low-cost platform enabling a rapid production ramp-up.

• Commercial Timeline: Initial customers expected by end of Q2 2026; software enhancements (e.g., variable bolus, improved alarms, ACE/AID compatibility) in development; CE Mark targeted Q4 2026/Q1 2027.

Targeting Q1 2026 Launch, Subject to FDA Clearance

Key Highlights:

• Cartridge & Infusion Set Lots in Production: Validation production lots now being produced for launch, derisking commercial-scale production.

• First Removable Tubeless Patch Pump: Pivot targets underserved "almost-pumpers" - adults with diabetes hesitant to move from multiple daily injections (MDI) due to cost and complexity - representing a significant portion of the growing ~$8 billion global insulin pump market.

• Affordable, User-Friendly Design: A full 3ml removable cartridge and pump with a simple interface expands access for millions managing diabetes with MDI by providing significant clinical therapy improvement

Study to Deliver Insulin to Internal Testers Wearing Continuous Glucose Monitors

-Targets $3 Billion "Almost-Pumper" Market with First Simplified and Removable/Replaceable Insulin Patch Pump

- Aims to Improve Patient and Clinician Experience for the Care of Diabetes

Key Highlights:

• Pivot Controller Line Validated: Manufacturing line has now been validated for human-use production in support of expected Q1 2026 market launch.

• Pivot will be First Two-Part Tubeless Patch Pump: Pivot, a 3 milliliter removable patch pump, targets the $3 billion dollar market for adult "almost-pumpers" with its affordable, user-friendly, easy-to-learn design.

High-Volume Manufacturing Readiness: Modular Medical's scalable platform positions it to target a significant share of the insulin pump market.

Key Highlights:

• Pivot continues to progress toward CE Mark certification in 2026

• Stage 1 ISO Audit completed with Stage 2 planned for 1H2026

-Seasoned Executive with Proven Track Record in International Pump Launches to Accelerate Global Adoption of User Friendly, Affordable Patch Pumps

-Study to Evaluate Usability and Extended Wear for Next-Generation Tubeless Patch Pump

- Use of MODD1 on clinicians with Type 1 diabetes

-More than 6,000 MODD1 cartridges produced

- Conversion to Pivot-ready manufacturing in preparation for product launch in 1Q26

-Debuting a "coming soon" campaign for tubeless Pivot patch pump

- Expects special 510(k) filing for Pivot product in October

- Will introduce first level of its gamified training application developed by Level Ex, developers of the Level One diabetes-management game

- Use of MODD1 on clinician with Type 1 diabetes

- Modular Medical intends to deploy the MODD1 on a larger number of clinicians in mid August

-Line has been in production at risk since early July
- Production to continue until late August when conversion to Pivot manufacturing will begin

- Engaged BSI Group to start the process of obtaining regulatory clearance of the MODD1, next-generation insulin pump for the European market

- Targeting Q1 2026 for expected clearance of the MODD1 in the E.U.

-Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements

-Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough

• Meet with Modular Medical CEO, Jeb Besser

• Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association

• About half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks

• Discover Modular Medical's Recently Announced Results from a Successful GLP-1 Proof of Concept Study

-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery

- Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone

-Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility

-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024

-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations

-CEO to discuss further details of the program in Tribe Public Webinar on Wednesday, September 11 at 8:30 a.m. Pacific time

• Meet with Modular Medical CEO, Jeb Besser

• There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin injection. Only 20% currently use an insulin pump.

• Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association

• About half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks

• MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetes

• Designed to be simpler and more affordable to expand access to diabetes technology for previously underserved communities

• Commercial availability expected in early 2025

Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations